BCL6公司
弥漫性大B细胞淋巴瘤
生发中心
淋巴瘤
起源细胞
亚型
生物
病理
表型
滤泡性淋巴瘤
比较基因组杂交
癌症研究
荧光原位杂交
B细胞
基因
医学
遗传学
染色体
抗体
计算机科学
程序设计语言
作者
Vanesa‐Sindi Ivanova,John R. Davies,Thomas Menter,Damian Wild,Anne Müller,Fatime Krasniqi,Frank Stenner,Alexandros Papachristofilou,Stefan Dirnhofer,Alexandar Tzankov
摘要
Aims Primary bone diffuse large B‐cell lymphoma (PB‐DLBCL) is not recognized as a separate entity by the current classification systems. Here we define and highlight its distinctive clinical presentation, morphology, phenotype, gene expression profile (GEP), and molecular genetics. Methods We collected 27 respective cases and investigated their phenotype, performed gDNA panel sequencing covering 172 genes, and carried out fluorescence in situ hybridization to evaluate MYC , BCL2, and BCL6 translocations. We attempted to genetically subclassify cases using the Two‐step classifier and performed GEP for cell‐of‐origin subtyping and in silico comparison to uncover up‐ and downregulated genes as opposed to other DLBCL. Results Most cases ( n = 22) were germinal centre B‐cell‐like (GCB) by immunohistochemistry and all by GEP. Additionally, PB‐DLBCL had a mutational profile similar to follicular lymphoma and nodal GCB‐DLBCL, with the exception of more frequent TP53 and B2M mutations. The GEP of PB‐DLBCL was unique, and the frequency of BCL2 rearrangements was lower compared to nodal GCB‐DLBCL. The Two‐step classifier categorized eight of the cases as EZB, three as ST2, and one as MCD. Conclusion This study comprehensively characterizes PB‐DLBCL as a separate entity with distinct clinical and morpho‐molecular features. These insights may aid in developing tailored therapeutic strategies and shed light on its pathogenesis.
科研通智能强力驱动
Strongly Powered by AbleSci AI